Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

30 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The role of glucocorticoid receptors in metabolic syndrome and psychiatric illness.
Moraitis AG, Block T, Nguyen D, Belanoff JK. Moraitis AG, et al. Among authors: belanoff jk. J Steroid Biochem Mol Biol. 2017 Jan;165(Pt A):114-120. doi: 10.1016/j.jsbmb.2016.03.023. Epub 2016 Mar 18. J Steroid Biochem Mol Biol. 2017. PMID: 27002803 Free article. Review.
Rapid reversal of psychotic depression using mifepristone.
Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Belanoff JK, et al. J Clin Psychopharmacol. 2001 Oct;21(5):516-21. doi: 10.1097/00004714-200110000-00009. J Clin Psychopharmacol. 2001. PMID: 11593077 Clinical Trial.
An open label trial of C-1073 (mifepristone) for psychotic major depression.
Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF. Belanoff JK, et al. Biol Psychiatry. 2002 Sep 1;52(5):386-92. doi: 10.1016/s0006-3223(02)01432-4. Biol Psychiatry. 2002. PMID: 12242054 Clinical Trial.
C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease.
DeBattista C, Belanoff J. DeBattista C, et al. Curr Alzheimer Res. 2005 Apr;2(2):125-9. doi: 10.2174/1567205053585954. Curr Alzheimer Res. 2005. PMID: 15974908 Review.
The use of mifepristone in the treatment of neuropsychiatric disorders.
DeBattista C, Belanoff J. DeBattista C, et al. Trends Endocrinol Metab. 2006 Apr;17(3):117-21. doi: 10.1016/j.tem.2006.02.006. Epub 2006 Mar 10. Trends Endocrinol Metab. 2006. PMID: 16530421 Review.
Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.
DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G. DeBattista C, et al. Biol Psychiatry. 2006 Dec 15;60(12):1343-9. doi: 10.1016/j.biopsych.2006.05.034. Epub 2006 Aug 4. Biol Psychiatry. 2006. PMID: 16889757 Clinical Trial.
2-Benzenesulfonyl-8a-benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists.
Clark RD, Ray NC, Blaney P, Crackett PH, Hurley C, Williams K, Dyke HJ, Clark DE, Lockey PM, Devos R, Wong M, White A, Belanoff JK. Clark RD, et al. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5704-8. doi: 10.1016/j.bmcl.2007.07.055. Epub 2007 Aug 19. Bioorg Med Chem Lett. 2007. PMID: 17822897
1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity.
Clark RD, Ray NC, Williams K, Blaney P, Ward S, Crackett PH, Hurley C, Dyke HJ, Clark DE, Lockey P, Devos R, Wong M, Porres SS, Bright CP, Jenkins RE, Belanoff J. Clark RD, et al. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1312-7. doi: 10.1016/j.bmcl.2008.01.027. Epub 2008 Jan 11. Bioorg Med Chem Lett. 2008. PMID: 18226897
A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction.
Blasey CM, Debattista C, Roe R, Block T, Belanoff JK. Blasey CM, et al. Contemp Clin Trials. 2009 Jul;30(4):284-8. doi: 10.1016/j.cct.2009.03.001. Epub 2009 Mar 24. Contemp Clin Trials. 2009. PMID: 19318138 Clinical Trial.
Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
Gross C, Blasey CM, Roe RL, Belanoff JK. Gross C, et al. Obesity (Silver Spring). 2010 Dec;18(12):2295-300. doi: 10.1038/oby.2010.51. Epub 2010 Mar 25. Obesity (Silver Spring). 2010. PMID: 20339369 Clinical Trial.
30 results
Jump to page